



BRITISH GENERIC MANUFACTURERS ASSOCIATION

June 20th, 2012

## BGMA Appoints New Chair

The British Generic Manufacturers Association (BGMA) has appointed Kim Innes, a commercial director responsible for Teva UK Limited's generics business, as its new Chair for the next two years.

She replaces Michael Cann, a director with Actavis, who will continue for a further year as vice-chair of the association, which is the generic industry's trade body representing more than 90 per cent of the UK supply market.

Kim, who has worked in the generics industry since 1991, said: "I am really pleased and honoured to be heading up the association at a critical time for the industry as a whole. Michael has made a great contribution over his past two years as Chair, and has overseen a very busy time for the association both in the UK and more widely in Europe. Over the coming two years, we will build on the progress we've already made, and continue to focus on our three core objectives of increasing patient access to medicines, maintaining market efficiency and providing economic sustainability for the industry.

"Industry sustainability is particularly important right now. Generic manufacturers are under constant pressure to do more for less and it is crucial we do not undermine the uniquely successful competitive market we have in the UK by a continued downward pressure on pricing. To this end we have recently agreed a partnership with the Government to explore what can be done around industry sustainability.

"Generic medicines save the NHS around £9billion a year from the drugs bill, and act as a strong incentive for the research based industry to develop much needed, new, truly innovative medicines for patients.

"It is important this value and innovation incentive role is recognised widely, as without it the NHS would have some very difficult decisions to make on funding priorities. The BGMA has very good relationships with Government, regulators and our peer group and I look forward to continuing those relationships and working with these groups to ensure that access, efficiency and sustainability remain top of the agenda."

ENDS

For further information contact:

Jeremy Durrant, 0207 866 7883 / 07792 918648

Press Release

[Jeremy.durrant@britishgenerics.co.uk](mailto:Jeremy.durrant@britishgenerics.co.uk)

Notes for Editors:

The British Generic Manufacturers Association represents the interests of UK-based manufacturers and suppliers of generic medicines and promotes the development and understanding of the generic medicines industry in the United Kingdom.

Generic medicines contain the same active ingredient and are as effective as the equivalent brand and cost much less, making the NHS drugs bill affordable. More than two thirds (67.4%) of all medicines dispensed by the NHS are generics yet they cost only 29.6% of the NHS drugs bill, a saving of around £9.5bn\* in England & Wales alone. Without generics, the NHS drugs bill would be approximately twice its current level. The average cost to the NHS of a generic medicine is £4.01, whilst the average cost of a branded medicine is £19.73. Competition from generics also stimulates the research based pharmaceutical industry to develop new medicines.

Our 24 members account for around 90% of the UK generics market by volume. Their work keeps medicines affordable for the Department of Health which allows further investment in other healthcare priorities, and promotes innovation in the development of new medicines.

We represent the views and interests of our members and industry to the UK government, the devolved administrations, regulators, other relevant third parties, including where appropriate the Institutions of the European Union.

\* The saving of £9.5bn per year due to generic competition is based on a calculation of what the NHS drugs bill would be if all prescription medicines cost the NHS the average price of branded drugs, i.e. without the impact of lower priced generic medicines.